ISRCTN31262122
Completed
未知
PRotective vEntilation with veno-venouS lung assisT in respiratory failure
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Belfast Health & Social Care Trust
- Enrollment
- 412
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34463700/ (added 20/05/2022) 2023 Other publications in https://doi.org/10.3310/fcdq8036 cost-utility analysis (added 17/10/2023)
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Invasive mechanical ventilation using PEEP \= 5cmH2O\*
- •2\. Acute and potentially reversible cause of acute respiratory failure as determined by the treating physician
- •3\. Within 48 hours of the onset of hypoxaemia as defined by PaO2/FiO2 \= 20kPa\*\*
- •\*Recommended on low tidal volume ventilation \= 6 ml/kg PBW
- •\*\*Requires two ABG with a PaO2/FiO2 \= 20kPa separated by at least 6 hours. 48 hour duration begins at the time of 2nd ABG demonstrating PaO2/FiO2 ratio \= 20kPa. Added 05/03/2019: Site will then have a further 8 – 24 hours to randomise and administer the intervention. Added 23/05/2017: The onset of hypoxaemia is from time of intubation and invasive ventilation.
- •(ABGs with PaO2/FiO2 \= 20kPa are permitted between the two trial inclusion ABGs).
Exclusion Criteria
- •Current exclusion criteria as of 23/05/2017:
- •1\. Age \<16 years old
- •2\. Intubated and mechanically ventilated via an endotracheal or tracheostomy tube \= 7 days (168 hours) up to the time of randomisation
- •3\. Ability to maintain Vt to \= 3ml/kg PBW while maintaining pH \= 7\.2 as determined by the treating physician
- •4\. Receiving, or decision to commence, ECMO in the next 24 hours.
- •5\. Mechanical ventilation using HFOV or APRV
- •6\. Untreated pulmonary embolism, pleural effusion or pneumothorax as the primary cause of acute respiratory failure.
- •7\. Acute respiratory failure fully explained by left ventricular failure or fluid overload (May be determined by clinical assessment or echocardiography/cardiac output monitoring).
- •8\. Left ventricular failure requiring mechanical support
- •9\. Contra\-indication to limited systemic anticoagulation with heparin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
pRotective vEntilation With Veno-venouS Lung assisT in Respiratory FailureAcute Respiratory Failure With HypoxiaNCT02654327Belfast Health and Social Care Trust1,120
Active, not recruiting
Not Applicable
Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AFAtrial FibrillationNCT06099730Massachusetts General Hospital360
Withdrawn
Not Applicable
Rivet PVS Therapy in Group 2 PH-HFpEFHeart FailurePulmonary HypertensionNCT05205265NXT Biomedical
Withdrawn
Not Applicable
Rivet PVS Therapy in Group 2 PH-HFpEF CanadaHeart FailurePulmonary HypertensionNCT05332873NXT Biomedical
Unknown
Phase 2
Atrial Ganglionated Plexi Ablation Guided by the SUMO Technology With and Without Conventional Pulmonary Vein Isolation in Patients With Persistent AFAtrial FibrillationNCT02492256Meshalkin Research Institute of Pathology of Circulation60